- Gold HK, Gimple LW, Yasuda T, et al. Pharmacodynamic study of F(ab') fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 96: 651-659.
- The IMPACT II Investigators. Effects of competitive platelet glycoprotein IIb/IIIa inhibition with Intergrilin in reducing complications of percutaneous coronary intervention. Lancet 1997; 349: 1422-1428.
- The RESTORE investigators. Effect of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-1453.
- Ellis SG, Navetta FI, Tcheng JT, et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty: an initial experience. Coron Artery Dis 1993; 4: 167-175.
- Simoons ML, de Boer MJ, van den Brand MJBM, et al; and the European Cooperative Study Group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
- The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
- Topol EJ, Ferguson JJ, Weisman HF, et al, for the EPIC Investigator Group. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin 3 blockade with percutaneous coronary intervention. JAMA 1997; 278: 479-484.
- The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-1435.
- Topol EJ, Califf RM, Lincoff AM, et al., for the EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.
- The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
- Brener SJ, Barr LA, Burchenal J, et al; on behalf of the ReoPro and Primary PTCA organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734-741.
- Mark DB, Talley JD, Topol EJ, et al; for the EPIC Investigators. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996; 94: 629-635.
- Ellis SG, Lincoff AM, Topol EJ. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. J Am Coll Cardiol 1998; 32: 1619-1623.
- Blankenship J, Anderson M, Tcheng J. In-lab angiographic complications during coronary intervention with abciximab vs placebo in the EPILOG Trial. Circulation 1997; 96: I-162 (abstr.).
- Khan MM, Ellis SG, Aquirre FV, et al. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. J Am Coll Cardiol 1998; 31: 31-36.
- The EPIC Investigator Group. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin B3 blockade with percutaneous coronary intervention. JAMA 1997; 278: 479-484.
- Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for non-cardiac surgery. Report of the ACC/AHA Task Force on Practice Guidelines. J Am Coll Cardiol 1996; 27: 910-948.
- Grines C, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673-679.
- Grines C, Stone G, O'Neill W. The PAMI (Primary Angioplasty in Myocardial Infarction) studies: An overview. J Interven Cardiol 1998; 11: 87-99.
- Grines C, Cox D, Morice MC. Stent PAMI: Primary endpoint results of a multicenter randomized trial of heparin coated stenting vs primary PTCA for AMI. Circulation 1998; 98 (Suppl I): I-22 (abstr.).
- Ellis SG, Whitlow P, Topol EJ. A highly significant 40% reduction in ischemic complications of percutaneous coronary intervention in 1995: Beginning of a new era. J Am Coll Cardiol 1996; 27: I-253A (abstr.).
- Lincoff AM, Mark DB, Topol EJ. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade during coronary intervention in the EPILOG trial. J Am Coll Cardiol 1997; 29: I-240A (abstr.).
- The EPIC Investigators. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996; 94: 629-635.
- Rodriguez O, Cutlip DE, Kuntz RE, Cohen DJ. Cost-effectiveness of abciximab after coronary stenting: A decision-analytic model. J Am Coll Cardiol 1998; 31: I-51A (abstr.).
- Balsano F, Rizzon P, Rudelli G. Antiplatelet treatment with ticlopidine in unstable angina. Circulation 1990; 82: 17-26.
- Schörnig A, Neuman FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089.
- Curzen NP, Rothman MT. The role of the interventionalist in unstable angina. In: Ferguson, Purcell, Eds. Update in Unstable Angina. London UK: Royal Society of Medicine Press,1999 (in press).
- Stables RH. Routine use of abciximab in coronary stenting? Lancet 1998; 352: 81.
- Kantor B, Schwartz RS. The role of thrombus in stent restenosis. Acute Coronary Syndromes 1998; 1: 90-98.
- Espinola-Klein C, Rupprecht HJ Erbel R, Nafe B, Brennecke R, Meyer J. Impact of restenosis 10 years after coronary angioplasty. Eur Heart J 1998; 19: 1047-1053.
- Eberli FR, Meier B. Restenosis after angioplasty: an Achilles heel well covered up. Eur Heart J 1998; 19: 976-977.
- Baim DS, Carrozza JP. Stent thrombosis. Circulation 1997; 95: 1098-1110.
- Leftowitz RJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559.
- Haas TA, Plow EF. Integrin ligand interactions: a year in review. Curr Opinions Cell Biol 1994; 6: 656-662.
- Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988; 71: 831-843.
- Newman PJ, Valentin N. Human platelet alloantigens: recent findings, new perspectives. Thromb Haemostasis 1995; 74: 234-239.
- Newman PJ, Derbes R, Aster RH. The human platelet alloantigens, PI and PI, are associated with a leucine 33/proline 33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-1781.
- Wiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor is an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-1094.
- Marian AJ, Brugada R, Kleinman NS. Platelet glycoprotein IIIa PI polymorphism and myocardial infarction. N Engl J Med 1996; 335: 1071-1072.
- Osborn SV, Hampton KK, Smillie D, Channer KS, Daly ME. Platelet glycoprotein IIIa gene polymorphism and myocardial infarction. Lancet 1996; 348: 1309-1310.
- Samani NJ, Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res 1997 1997; 33: 693-697.
- Idker PM, Hennekens CH, Schmitz, et al. PI polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis. Lancet 1997; 349: 385-388.
- Curzen NP, Goodall AH, Hurd C, et al. Stimulated platelets of patients with the PI allele for platelet membrane GPIIIa exhibit increased fibrinogen binding. Eur Heart J 1998; 19 (Suppl): 360.
- Pytela R, Pierschbacher MD, Ginsberg MH, et al. Platelet membrane glycoprotein IIb/IIIa: member of a family of RGD specific adhesion receptors. Science 1986; 231: 1559-1562.
- Ruggeri ZM, De Marco L, Gatti L, Bader R, Montgomery RR. Platelets have more than one binding site for von Wille-brand factor. J Clin Invest 1983; 72: 1-12.
- Pierschbacher MD, Rouslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30-33.
- Conforti G, Dominguew-Jiminez C, Zanetti A, et al. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood 1992; 80: 1893-1900.
- Choi ET, Engel L, Callow AD, et al. Inhibition of neointimal hyperplasia by blocking 3v33 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994; 19: 125-134.
International Journal of Cardiovascular Interventions
Volume 2, 1999 - Issue 1